# US 12,178,795 B2 · Method for treating metastatic prostate cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,178,795 B2 - Document ID: US12178795B2 - Status: Granted - Kind: B2 - Application number: 18/139,029 - Filed: 2023-04-25 - Published: 2023-08-17 - Granted: 2024-12-31 - Earliest claimed: 2012-07-26 - Assignees: The William Yarbrough Foundation - Applicants: The William M Yarbrough Foundation - Inventors: Michael E Silver - Web page: https://patentgrep.com/patent/US12178795B2 ## CPC - A61K 31/26: Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 31/16: Amides, e.g. hydroxamic acids - A61K 31/195: having an amino group - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A method for treating benign prostatic hyperplasia (BPH), prostatitis, and/or prostate cancer, including the step of administering an isothiocyanate functional surfactant to a patient affected by benign prostatic hyperplasia, prostatitis, and/or prostate cancer. In a preferred embodiment, the protonated form of the isothiocyanate functional surfactant is represented by the following chemical structure: ## Claims ### Claim 1 A method of treating metastatic prostate cancer comprising the step of: administering a product to a patient having metastatic prostate cancer wherein the product comprises: an isothiocyanate functional surfactant; one or more solvents; and at least one an additional surfactant chosen from the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. ### Claim 2 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the isothiocyanate functional surfactant is administered to the patient at least one of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, and nasally. ### Claim 3 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the product is administered by applying the product to skin and the method treating metastatic prostate cancer further comprises a step of removing the product from skin of the patient a period of time after the product is applied to the skin. ### Claim 4 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the at least one an additional surfactant consists of at least one non-ionic surfactant and the at least one non-ionic surfactant is chosen from a group consisting of: alcohols, alkanolamides, amine oxides, esters, ethers, silicone copolyols, cetearyl alcohol, ceteareth-20, nonoxynol-9, C12-15 pareth-9, POE(4) lauryl ether, cocamide DEA, glycol distearate, glyceryl stearate, PEG-100 stearate, sorbitan stearate, PEG-8 laurate, polyglyceryl-10 trilaurate, lauryl glucoside, octylphenoxy-polyethoxyethanol, PEG-4 laurate, polyglyceryl diisostearate, polysorbate-60, PEG-200 isostearyl palmitate, sorbitan monooleate, polysorbate-80 and combinations thereof. ### Claim 5 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the at least one an additional surfactant consists of at least one anionic surfactant and the at least one anionic surfactant is chosen from a group consisting of: taurates; isethionates; alkyl and alkyl ether sulfates; succinamates; alkyl sulfonates, alkylaryl sulfonates; olefin sulfonates; alkoxy alkane sulfonates; sodium and potassium salts of fatty acids derived from natural plant or animal sources or synthetically prepared; sodium, potassium, ammonium, and alkylated ammonium salts of alkylated and acylated amino acids and peptides; alkylated sulfoacetates; alkylated sulfosuccinates; acylglyceride sulfonates, alkoxyether sulfonates; phosphoric acid esters; phospholipids, ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium stearoyl isethionate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium lauryl sarcosinate, disodium laureth sulfosuccinate, sodium lauryl sulfoacetate, sodium cocoyl glutamate, TEA-cocoyl glutamate, TEA cocoyl alaninate, sodium cocoyl taurate, potassium cetyl phosphate and combinations thereof. ### Claim 6 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the at least one an additional surfactant consists of at least one cationic surfactant and wherein the cationic surfactant is chosen from a group consisting of: alkylated quaternary ammonium salts R4NX; alkylated amino-amides (RCONH—(CH2)n)NR3X; alkylimidazolines; alkoxylated amines, cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl ammonium bromide, lauryl dimethyl ammonium chloride, lauryl dimethyl ammonium bromide, stearyl dimethyl ammonium chloride, stearyl dimethyl ammonium bromide, cetyl trimethyl ammonium chloride, cetyl trimethyl ammonium bromide, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, lauryl dimethyl ammonium chloride, stearyl dimethyl cetyl ditallow dimethyl ammonium chloride, dicetyl ammonium chloride, dilauryl ammonium chloride, dilauryl ammonium bromide, distearyl ammonium chloride, distearyl ammonium bromide, dicetyl methyl ammonium chloride, dicetyl methyl ammonium bromide, dilauryl methyl ammonium chloride, distearyl methyl ammonium chloride, distearyl methyl ammonium bromide, ditallow dimethyl ammonium chloride, ditallow dimethyl ammonium sulfate, di(hydrogenated tallow) dimethyl ammonium chloride, di(hydrogenated tallow) dimethyl ammonium acetate, ditallow dipropyl ammonium phosphate, ditallow dimethyl ammonium nitrate, di(coconutalkyl) dimethyl ammonium chloride, di(coconutalkyl) dimethyl ammonium bromide, tallow ammonium chloride, coconut ammonium chloride, stearamidopropyl PG-imonium chloride phosphate, stearamidopropyl ethyldimonium ethosulfate, stearimidopropyldimethyl (myristyl acetate) ammonium chloride, stearamidopropyl dimethyl cetearyl ammonium tosylate, stearamidopropyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate, ditallowyl oxyethyl dimethyl ammonium chloride, behenamidopropyl PG dimonium chloride, dilauryl dimethyl ammonium chloride, distearly dimethyl ammonium chloride, dimyristyl dimethyl ammonium chloride, dipalmityl dimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearamidoproyl PG-dimonium chloride phosphate, stearamidopropyl ethyldiammonium ethosulfate, stearamidopropyl dimethyl (myristyl acetate) ammonium chloride, stearimidopropyl dimethyl cetaryl ammonium tosylate, stearamido propyl dimethyl ammonium chloride, stearamidopropyl dimethyl ammonium lactate and combinations thereof. ### Claim 7 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the at least one an additional surfactant consists of at least one zwitterionic surfactant and wherein the zwitterionic surfactant is chosen from the group consisting of betaines; sultaines; hydroxysultaines, amido betaines, amidosulfo betaines, cocoamidopropyl sultaine, cocoamidopropyl hydroxyl sultaine, cocoamidopropylbetaine, coco dimethyl carboxymethyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alphacarboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, cetyl dimethyl betaine, lauryl (2-bishydroxy) carboxymethyl betaine, stearyl bis-(2-hydroxyethyl) carboxymethyl betaine, oelyl dimethyl gamma-carboxypropyl betaine, lauryl bis-(2-hydroxypropyl) alpha carboxymethyl betaine, coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis (2-hydroxyethyl) sulfopropyl betaine, oleyl betaine, cocamidopropyl betaine and combinations thereof. ### Claim 8 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the patient is a mammal. ### Claim 9 (depends on 8) The method of treating metastatic prostate cancer of claim 8, wherein the mammal is a human. ### Claim 10 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the one or more solvents comprises a solvent chosen from the group consisting of silicone based solvents, silicon based fluids, mineral oil, vegetable oils, and squalene. ### Claim 11 (depends on 1) The method treating metastatic prostate cancer of claim 1, wherein the product is a topical preparation selected from a group consisting of ointment, cream, emulsion, lotion and gel. ### Claim 12 A method of treating metastatic prostate cancer comprising the steps of: contact a product to a part of a human affected by metastatic prostate cancer wherein the product comprises a first surfactant or pharmaceutically acceptable salt thereof and a second surfactant to an area affected by metastatic prostate cancer wherein the first surfactant is represented by the following chemical structure: wherein R1 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; wherein R2 comprises NCS; wherein R3-R5 are the same or different and comprise H; OH; an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer with the proviso that at least one of R3-R5 comprise an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 8 to approximately 25 carbon atom(s), wherein X comprises a counter cation such as, but not limited to, alkali metals, alkaline earth metals, transition metals, s-block metals, d-block metals, p-block metals, NZ4+, wherein Z comprises, H, R6, OR6, and wherein R6 comprises an alkyl, cycloalkyl, polycycloalkyl, heterocycloalkyl, aryl, alkaryl, aralkyl, alkoxy, alkanoyl, aroyl, alkenyl, alkynyl and/or cyano group containing approximately 1 to approximately 25 carbon atom(s), wherein the carbon atom(s) may be a linking group to, or part of, a halogen, a N, O, and/or S containing moiety, and/or one or more functional groups comprising alcohols, esters, ammonium salts, phosphonium salts, and combinations thereof; a linkage to a dimer; a linkage to an oligomer; and/or a linkage to a polymer; and wherein the product further comprises one or more solvents. ### Claim 13 (depends on 12) The method of treating metastatic prostate cancer of claim 12, wherein the one or more solvents comprises a solvent chosen from the group consisting of silicone based solvents, silicon based fluids, mineral oil, vegetable oils, and squalene; and wherein first surfactant elevates phase II enzymes. ### Claim 14 (depends on 12) The method of treating metastatic prostate cancer of claim 12, wherein first surfactant elevates phase II enzymes. ### Claim 15 A method of treating metastatic prostate cancer comprising the steps of: applying a product containing a surfactant or pharmaceutically acceptable salt thereof to an area of a patient affected by metastatic prostate cancer wherein the surfactant is represented by the following chemical structure: wherein R1 is selected from the group consisting of an alkyl group containing 1 to 25 carbon atom(s); wherein R2 is selected from the group consisting of NCS; and wherein R3-R5 are each independently selected from the group consisting of H; OH; and an alkyl, and alkanoyl group containing 1 to 25 carbon atom(s) with the proviso that at least one of R3-R5 is selected from the group consisting of an alkyl, and alkanoyl, group containing 8 to 25 carbon atoms; and wherein X comprises a counter cation; and wherein the product further comprises one or more solvents. ### Claim 16 (depends on 15) The method of treating metastatic prostate cancer of claim 15, wherein the patient is a human and the surfactant or pharmaceutically acceptable salt thereof is in a protonated form represented by the following chemical structure: ### Claim 17 (depends on 14) The method of treating metastatic prostate cancer of claim 14 further comprising a step of administering an additional surfactant chosen from the group comprising a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant, and combinations thereof. ### Claim 18 (depends on 1) The method of treating metastatic prostate cancer of claim 1, wherein the product is applied to the patient in a way chosen from the group consisting of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, and nasally. ### Claim 19 (depends on 1) The method of claim 1, wherein the isothiocyanate functional surfactant further comprises one or more pharmaceutical, biological or molecular biological active agents. ### Claim 20 (depends on 12) The method of treating metastatic prostate cancer of claim 12, wherein the product is applied to a patient in a way chosen from the group consisting of orally, intravenously, intramuscularly, intrathecally, cutaneously, subcutaneously, transdermally, sublingually, buccally, rectally, and nasally.